Neil Feldman, DO
Allergy · Allentown, PANPI 1699742486
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 36.4% of the total.
Across 144 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$495
- CSL Behring$213
- Takeda Pharmaceuticals U.S.A., Inc.$185
- Biocryst US Sales Co., LLC$167
- Genentech USA, Inc.$157
- plus $621 from 10 others
What the payments were for
- Food & beverage$2,891100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,052 |
| GSK | 30 | $495 |
| CSL Behring | 8 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $185 |
| Biocryst US Sales Co., LLC | 7 | $167 |
| Genentech USA, Inc. | 9 | $157 |
| Novartis | 8 | $135 |
| Amgen | 5 | $105 |
| Sanofi | 4 | $103 |
| Pharming Healthcare, Inc. | 4 | $86 |
| Teva Pharmaceuticals USA, Inc. | 4 | $50 |
| Pfizer | 2 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| Alk-abello, Inc | 1 | $30 |
| Mylan Specialty L.p. | 1 | $19 |
| LEO Pharma Inc. | 1 | $13 |
How this compares
$2,891 in reported general payments places this provider in the 55th percentile of 25 allergy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FasenraBenralizumab | 12 | $69,073 |
| Breo ElliptaFluticasone/Vilanterol | 121 | $57,789 |
| Dupixent PenDupilumab | 12 | $42,141 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $26,286 |
| SymbicortBudesonide/Formoterol Fumarate | 70 | $24,375 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 67 | $17,599 |
| DuleraMometasone/Formoterol | 34 | $13,753 |
| Arnuity ElliptaFluticasone Furoate | 36 | $13,361 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $13,170 |
| Spiriva RespimatTiotropium Bromide | 22 | $13,079 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $10,771 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $7,287 |
| Montelukast Sodium | 434 | $7,053 |
| Epinephrine | 33 | $7,042 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $5,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $495 | $97,436201 claims |
| AstraZenecaFasenra, Symbicort, Pulmicort Flexhaler | $1,052 | $97,43196 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $38 | $20,36735 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $50 | $4,84218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 25 allergy providers in Pennsylvania.
Other allergy in Allentown
- Schweta ArakaliAllentown$12K
- Michael PalumboPittsburgh$561K
- James DeangeloPittsburgh$79K
- Shannon KearneyBethlehem$48K
- Rehan MujahidWind Gap$16K
- Michelle WeissYork$7K
- David MillerPittsburgh$7K
- Andrew MurphyWest Chester$6K
- Victoria CorreaDoylestown$3K
- Thomas MakinWexford$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.